Ainuovirine clinical trials
Also written KM-023.
How each study uses ainuovirine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Keep track of what changes. Save the ainuovirine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesApprovals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- KM-023
- 3
Studies by the year they started
4 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2025 | 1 |
| 2026 | 2 |
Who runs them
Industry 1 · Other 3
Orvida Pharma (formerly Kamari Pharma) (2) · Kainos Medicine Inc. (1) · Shanghai Public Health Clinical Center (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test ainuovirine.
- Nov 2026Study of KM-023 in Healthy Volunteers and Patients With Olmsted Syndrome.Phase 1 · Orvida Pharma (formerly Kamari Pharma)
- Apr 2027Safety, Tolerability, and Efficacy of Oral KM-023 in Adult Patients With Pachyonychia Congenita (pEDD-PC)Phase 2 · Orvida Pharma (formerly Kamari Pharma)
Studies
Open first, then newest update. How each study uses ainuovirine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Safety, Tolerability, and Efficacy of Oral KM-023 in Adult Patients With Pachyonychia Congenita (pEDD-PC)Not yet recruitingPhase 2Orvida Pharma (formerly Kamari Pharma)NCT07893483Written as KM-023
- Comparative Trial Between Ainuovirine(ANV)/Lamivudine(3TC)/Tenofovir(TDF) and Efavirenz(EFV)/Lamivudine/Tenofovir RegimensNot yet recruitingPhase 4Shanghai Public Health Clinical CenterNCT07631897Written as Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets
- Study of KM-023 in Healthy Volunteers and Patients With Olmsted Syndrome.RecruitingPhase 1Orvida Pharma (formerly Kamari Pharma)NCT07090889Written as KM-023
- Single Ascending Dose (SAD)/Multiple Ascending Dose(MAD) Safety/Pharmacokinetic (PK) Study of KM-023CompletedPhase 1Kainos Medicine Inc.NCT01348516Written as KM-023